Laura Maiorino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Maiorino has a total of 269 co-authors. Here are the top co-authors by number of shared publications:
- Darrell J. Irvine
The Scripps Research Institute
40 shared publications - Byungji Kim
Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, USA
30 shared publications - Forest M. White
Department of Biological Engineering, Massachusetts Institute of Technology
29 shared publications - Jonathan Dye
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
29 shared publications - Stefani Spranger
Koch Institute for Integrative Cancer Research, Massachusetts Institute for Technology, Cambridge, MA, USA
29 shared publications - Heidi M. Temple
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, USA
28 shared publications
Latest Publications
- Open Access
- 18 December 2025
- Published by Springer Nature in Research Square
MHC-II antigen presentation on cancer cells improves CD4+ T cell immunity and vaccine efficacy
CD4+ T cells can be either protective or pathogenic in cancer [1-5], but how they interact with cancer cells to produce these effects remains poorly understood. Here, we developed a flexible autochthonous platform to introduce CD4+ T cell antigens in combination with CD8+ T cell antigens in a mouse lung cancer model. We found that tumor-specific CD4+ T cells potentiate CD8+ T cell control of tumor progression. Unlike previous studies emphasizing intratumoral interactions among dendritic cells, CD4+ T cells, and CD8+ T cells [4,5], we found that CD4+ T cell function and tumor control depend on direct antigen presentation by cancer cells via major histocompatibility complex class II (MHC-II). This direct interaction between cancer cells and CD4+ T cells led to increased immune infiltration, inflammatory remodeling, and sustained CD8+ T cell effector functions within tumors. Building on this, we demonstrate that tumor vaccination targeting both CD4+ and CD8+ T cell neoantigens significantly reduces tumor burden and requires cancer cell MHC-II presentation. These findings reveal an underappreciated mechanism of CD4+ T cell “help” and suggest a therapeutic approach targeting cancer cell presentation of MHC class II antigens.
- 18 December 2025
- Published by Springer Nature in Research Square
Open AccessMHC-II antigen presentation on cancer cells improves CD4+ T cell immunity and vaccine efficacy
CD4+ T cells can be either protective or pathogenic in cancer [1-5], but how they interact with cancer cells to produce these effects remains poorly understood. Here, we developed a flexible autochthonous platform to introduce CD4+ T cell antigens in combination with CD8+ T cell antigens in a mouse lung cancer model. We found that tumor-specific CD4+ T cells potentiate CD8+ T cell control of tumor progression. Unlike previous studies emphasizing intratumoral interactions among dendritic cells, CD4+ T cells, and CD8+ T cells [4,5], we found that CD4+ T cell function and tumor control depend on direct antigen presentation by cancer cells via major histocompatibility complex class II (MHC-II). This direct interaction between cancer cells and CD4+ T cells led to increased immune infiltration, inflammatory remodeling, and sustained CD8+ T cell effector functions within tumors. Building on this, we demonstrate that tumor vaccination targeting both CD4+ and CD8+ T cell neoantigens significantly reduces tumor burden and requires cancer cell MHC-II presentation. These findings reveal an underappreciated mechanism of CD4+ T cell “help” and suggest a therapeutic approach targeting cancer cell presentation of MHC class II antigens.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Peptide quantification in TMT labeled anti-flammatory macrophages and naïve macrophage
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Peptide quantification in TMT labeled anti-flammatory macrophages and naïve macrophage
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Supplementary Figure 3. Validation of co-culture upregulated macrophage presented peptides using GBM-KO cell co-culture.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Supplementary Figure 3. Validation of co-culture upregulated macrophage presented peptides using GBM-KO cell co-culture.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Supplementary Figure 7. Antigen presentation landscape of GBM tumor cells in macrophage co-culture.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Supplementary Figure 7. Antigen presentation landscape of GBM tumor cells in macrophage co-culture.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Protein expression quantification in TMT labeled GL261 or CT2A co-cultured macrophages and naïve macrophage
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Protein expression quantification in TMT labeled GL261 or CT2A co-cultured macrophages and naïve macrophage
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Peptide quantification in TMT labeled pro-inflammatory macrophages and naïve macrophage
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Peptide quantification in TMT labeled pro-inflammatory macrophages and naïve macrophage
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Supplementary Figure 11. Immunogenicity and therapeutic efficacy of mRNA vaccine encoding co-culture upregulated antigens.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Supplementary Figure 11. Immunogenicity and therapeutic efficacy of mRNA vaccine encoding co-culture upregulated antigens.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Supplementary Figure 4. NF-kb activation in GBM co-cultured macrophages.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Supplementary Figure 4. NF-kb activation in GBM co-cultured macrophages.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Copies per cell quantification of selected peptides
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
Copies per cell quantification of selected peptides
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 15 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
File map to PRIDE submission PXD057588
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 15 from Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
File map to PRIDE submission PXD057588